NCT05928286View on ClinicalTrials.gov

Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice

RecruitingOBSERVATIONAL
Enrollment

286

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Gallstone DiseaseObstructive Jaundice
Interventions
DRUG

Remaxol

The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)

Trial Locations (9)

Unknown

RECRUITING

Krai Clinical Hospital, Barnaul

RECRUITING

Hospital for War Veterans, Kazan'

RECRUITING

City Clinical Hospital No. 7, Nizhny Novgorod

RECRUITING

Pavlov Ryazan State Medical University, Ryazan

RECRUITING

Dzhanelidze St. Petersburg Research Institute of Emergency Medicine, Saint Petersburg

RECRUITING

St. Elizabeth Hospital, Saint Petersburg

RECRUITING

Samara State Medical University, Samara

RECRUITING

Mirotvortsev University Clinical Hospital No. 1, Saratov

RECRUITING

Kuvatov Republican Clinical Hospital, Ufa

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY